SNPMiner Trials (Home Page)
Report for SNP rs2305619
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
There is one clinical trial.
Clinical Trials
1 The 3q25 rs2305619 Polymorphism is Associated With Coronary Microvascular Obstruction Following Primary Angioplasty for Acute ST-segment Elevation Myocardial Infarction
The investigators enrolled 217 patients with acute STEMI undergoing primary PCI. The rs2305619 polymorphism was evaluated by real time PCR and plasma PTX3 concentration was assessed by human PTX3 ELISA kit.
NCT03907722 STEMI Microvascular Coronary Artery Disease Other: Long pentraxin 3 MeSH:Coronary Artery Disease
HPO:Coronary artery atherosclerosis
The 3q25 rs2305619 Polymorphism is Associated With Coronary Microvascular Obstruction Following Primary Angioplasty for Acute ST-segment Elevation Myocardial Infarction.
The 3q25 rs2305619 Polymorphism Associates With Microvascular Obstruction in STEMI The investigators enrolled 217 patients with acute STEMI undergoing primary PCI.
The rs2305619 polymorphism was evaluated by real time PCR and plasma PTX3 concentration was assessed by human PTX3 ELISA kit.
The rs2305619 polymorphism was evaluated by real time PCR and plasma PTX3 concentration was assessed by human PTX3 ELISA kit.
Primary Outcomes
Description: Percentage
Measure: Incidence of microvascular obstruction Time: Immediate after pciSecondary Outcomes
Description: Percentage
Measure: Incidence of mortality Time: 30 days